- Mucinous Cystadenoma of the Testis: A Case Report with Immunohistochemical Findings
-
Gilhyang Kim, Dohee Kwon, Hee Young Na, Sehui Kim, Kyung Chul Moon
-
J Pathol Transl Med. 2017;51(2):180-184. Published online February 13, 2017
-
DOI: https://doi.org/10.4132/jptm.2016.08.30
-
-
6,795
View
-
106
Download
-
5
Citations
-
 Abstract
 PDF
- Mucinous cystadenoma of the testis is a very rare tumor. Herein, we report a case of mucinous cystadenoma arising in the testis of a 61-year-old man, along with a literature review. Computed tomography showed a 2.5-cm-sized poorly enhancing cystic mass. Grossly, the tumor was a unilocular cystic mass filled with mucinous material and confined to the testicular parenchyma. Histologically, the cyst had a fibrotic wall lined by mucinous columnar epithelium without atypia. Immunohistochemical staining was positive for cytokeratin 20 and CDX2, as well as focally positive for cytokeratin 7. The pathologic diagnosis was mucinous cystadenoma.
-
Citations
Citations to this article as recorded by  - Cistoadenoma Mucinoso Paratesticular: Caso Interesante en el Instituto Guatemalteco de Seguridad Social
Edgar Estuardo González López, Carlos Gonzalo Estrada Pazos
Revista Guatemalteca de Urología.2023; 10(2): 16. CrossRef - Primary Borderline Mucinous Testicular Tumor: A Case Report and Literature Review
Changjuan Hao, Chunsong Kang, Xiaoyan Kang, Zhuanzhuan Yu, Tingting Li, Jiping Xue
Frontiers in Oncology.2021;[Epub] CrossRef - Ovarian-type Tumors (Mullerian Tumors) of the Testis: Clinicopathologic Findings with Recent Advances
Michelle S Lin, Alberto G Ayala, Jae Y Ro
annals of urologic oncology.2019; : 1. CrossRef - Borderline Mucinous Testicular Tumour: Diagnostic and Management difficulties
Krishan Pratap, Marlon Perera, Frances Malczewski, Rachel Esler
BMJ Case Reports.2018; : bcr-2017-223787. CrossRef - Mucinous tumor arising in a giant sacrococcygeal teratoma
Fengtian Zhang, Xiaolong Yu, Jin Zeng, Min Dai
Medicine.2017; 96(47): e8759. CrossRef
- Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma
-
Gilhyang Kim, Yul Ri Chung, Bohyun Kim, Boram Song, Kyung Chul Moon
-
J Pathol Transl Med. 2016;50(6):436-441. Published online October 10, 2016
-
DOI: https://doi.org/10.4132/jptm.2016.07.12
-
-
7,322
View
-
110
Download
-
2
Citations
-
Abstract
PDF
- Background
Human epidermal growth factor receptor 2 (HER2) is one of the known oncogenes in urothelial carcinoma. However, the association between HER2 and the prognosis of upper urinary tract urothelial carcinoma (UUTUC) has not yet been fully clarified. The aim of this study was to evaluate HER2 expression using the United States Food and Drug Administration (FDA) criteria and American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) criteria and compare their prognostic significance in UUTUC.
Methods
HER2 expression was evaluated in 144 cases of UUTUC by immunohistochemistry (IHC) using tissue microarrays. We separately analyzed HER2 expression using the FDA and ASCO/CAP criteria. The IHC results were categorized into low (0, 1+) and high (2+, 3+) groups.
Results
Using the FDA criteria, 94 cases were negative, 38 cases were 1+, nine cases were 2+, and three cases were 3+. Using the ASCO/CAP criteria, 94 cases were negative, 34 cases were 1+, 13 cases were 2+, and three cases were 3+. Four cases showing 2+ according to the ASCO/CAP criteria were reclassified as 1+ by the FDA criteria. High HER2 expression by both the FDA criteria and ASCO/CAP criteria was significantly associated with International Society of Urological Pathology high grade (p = .001 and p < .001). The high HER2 expression group classified with the FDA criteria showed significantly shorter cancer-specific survival (p = .004), but the HER2 high and low expression groups classified with the ASCO/CAP criteria did not show significant differences (p = .161) in cancer-specific survival.
Conclusions
HER2 high expression groups were significantly associated with shorter cancer-specific survival, and our study revealed that the FDA criteria are more suitable for determining HER2 expression in UUTUC.
-
Citations
Citations to this article as recorded by - Near-Infrared Photoimmunotherapy (NIR-PIT) in Urologic Cancers
Hiroshi Fukushima, Baris Turkbey, Peter A. Pinto, Aki Furusawa, Peter L. Choyke, Hisataka Kobayashi
Cancers.2022; 14(12): 2996. CrossRef - Assessment of HER2 Protein Overexpression and Gene Amplification in Renal Collecting Duct Carcinoma: Therapeutic Implication
Manuela Costantini, Carla Azzurra Amoreo, Liborio Torregrossa, Greta Alì, Enrico Munari, Carmen Jeronimo, Rui Henrique, Sara Petronilho, Umberto Capitanio, Roberta Lucianò, Nazareno Suardi, Maria Teresa Landi, Umberto Anceschi, Aldo Brassetti, Vito Michel
Cancers.2020; 12(11): 3345. CrossRef
|
